The financials
Merck & Co. by the numbers
Merck & Co. (MRK) reported revenue of $16.6B in Q2 2026 (quarter ended June 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 74% and net loss of $1.33B. For the full year FY2025, revenue was $65.0B (+1.3% year on year) and net income $18.3B. Its largest product in 2026-Q2 was Keytruda at $4.61B, 49% of the disclosed total, just ahead of Gardasil Gardasil9 at 5.7%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $16.6B | $15.8B | +5.1% |
| Gross profit | $12.2B | $12.2B | −0.3% |
| Net income | −$1.33B | $4.43B | to a loss |
| Diluted EPS | −$0.54 | $1.76 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Keytruda | $4.61B | 49% |
| Gardasil Gardasil9 | $542M | 5.7% |
| Winrevair | $522M | 5.5% |
| Bridion | $460M | 4.9% |
| Pro Quad MMRII Varivax | $438M | 4.6% |
| Keytruda Qlex | $395M | 4.2% |
| Companion Animal | $333M | 3.5% |
| Welireg | $214M | 2.3% |
| Ohtuvayre | $204M | 2.2% |
| Livestock | $202M | 2.1% |
| Lenvima | $194M | 2.1% |
| Alliancerevenue Lynparza | $167M | 1.8% |
| Other Pharmaceutical | $150M | 1.6% |
| Januvia | $149M | 1.6% |
| Prevymis | $147M | 1.6% |
| Capvaxive | $138M | 1.5% |
| Alliance Revenue Adempas Verquvo | $112M | 1.2% |
| Alliance Revenue Reblozyl | $98M | 1.0% |
| Rotateq | $84M | 0.9% |
| Adempas | $78M | 0.8% |
| Vaxneuvance | $69M | 0.7% |
| Zerbaxa | $44M | 0.5% |
| Isentress Isentress HD | $36M | 0.4% |
| Janumet | $28M | 0.3% |
| Delstrigo | $13M | 0.1% |
| Dificid | $11M | 0.1% |
| Alliance Revenue Koselugo | $10M | 0.1% |
| Verquvo | $9.0M | 0.1% |
| Lagevrio | $5.0M | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $9.46B (+1.9%)
Winrevair grew +62% year on yearLagevrio -94% year on year
Segment Latestquarter on quarteryear on year
- Keytruda$4.61B$4.61BQoQ +0.26%year on year -2.9%+0.26%-2.9%
- Gardasil Gardasil9$542.0M$542.0MQoQ +12%year on year -0.55%+12%-0.55%
- Winrevair$522.0M$522.0MQoQ +9.4%year on year +62%+9.4%+62%
- Bridion$460.0M$460.0MQoQ +7.7%year on year +12%+7.7%+12%
- Pro Quad MMRII Varivax$438.0M$438.0MQoQ +7.1%year on year -8.9%+7.1%-8.9%
- Keytruda Qlex$395.0M$395.0MQoQ +273%year on year -+273%-
- Companion Animal$333.0M$333.0MQoQ +8.1%year on year +7.8%+8.1%+7.8%
- Welireg$214.0M$214.0MQoQ +41%year on year +55%+41%+55%
- Ohtuvayre$204.0M$204.0MQoQ +56%year on year -+56%-
- Livestock$202.0M$202.0MQoQ -4.3%year on year +6.3%-4.3%+6.3%
- Lenvima$194.0M$194.0MQoQ +10%year on year +6.0%+10%+6.0%
- Alliancerevenue Lynparza$167.0M$167.0MQoQ +12%year on year -4.0%+12%-4.0%
- Other Pharmaceutical$150.0M$150.0MQoQ -9.6%year on year -18%-9.6%-18%
- Januvia$149.0M$149.0MQoQ -41%year on year -31%-41%-31%
- Prevymis$147.0M$147.0MQoQ +8.9%year on year +28%+8.9%+28%
- Capvaxive$138.0M$138.0MQoQ +17%year on year +7.0%+17%+7.0%
- Alliance Revenue Adempas Verquvo$112.0M$112.0MQoQ +2.8%year on year +3.7%+2.8%+3.7%
- Alliance Revenue Reblozyl$98.0M$98.0MQoQ -23%year on year +11%-23%+11%
- Rotateq$84.0M$84.0MQoQ -49%year on year +40%-49%+40%
- Adempas$78.0M$78.0MQoQ 0.00%year on year -2.5%0.00%-2.5%
- Vaxneuvance$69.0M$69.0MQoQ -44%year on year -49%-44%-49%
- Zerbaxa$44.0M$44.0MQoQ -15%year on year -2.2%-15%-2.2%
- Isentress Isentress HD$36.0M$36.0MQoQ +2.9%year on year -25%+2.9%-25%
- Janumet$28.0M$28.0MQoQ -59%year on year -59%-59%-59%
- Delstrigo$13.0M$13.0MQoQ +30%year on year -7.1%+30%-7.1%
- Dificid$11.0M$11.0MQoQ -54%year on year -87%-54%-87%
- Alliance Revenue Koselugo$10.0M$10.0MQoQ -94%year on year -77%-94%-77%
- Verquvo$9.0M$9.0MQoQ 0.00%year on year -18%0.00%-18%
- Lagevrio$5.0M$5.0MQoQ -82%year on year -94%-82%-94%
- Belsomra--QoQ -year on year ---
- Pifeltro--QoQ -year on year ---
- Pneumovax23--QoQ -year on year ---
- Remicade--QoQ -year on year ---
- Simponi--QoQ -year on year ---
Drug Manufacturers - General
Ranks #11 of 16 by Smart Score